Discovery Partnerships with Academia innovative medicines through - PowerPoint PPT Presentation

Discovery Partnerships with Academia innovative medicines through integrated partnerships

DPAc: A collaborative approach from GSK “ everyone playing to their strengths ” Deep biology and disease understanding of Academia Drug discovery expertise of GSK Build integrated partnerships that can translate innovative research into medicines that benefit patients

Key elements of DPAc Focus on the medicine  Collaborative partnerships focussed on drug discovery  Starts at any point from initiation of early screening, finishes with the medicine Undertake the best science  Minimal infrastructure – undertake projects independent of location or disease area  Access to all GSK drug discovery and development capabilities Share in the investment, share in the reward  Both sides contribute - looks for a complementary match of skills where GSK can make a positive contribution to success  Milestone funding with royalties. If GSK stops then the academic is free to continue and progress

Identifying potential DPAc opportunities What are we looking for: • Specific opportunities for drug discovery - therapeutics • Our scope covers almost all disease areas • Small molecule and biological (protein) modalities • Early stage discovery projects: its not necessary to have chemical assets or patents • Therapeutic hypothesis linking target / pathway to disease, built on e.g.: – genetic evidence, human expression data, in vitro cellular data, in vivo mechanistic models What we are not looking for: (other parts of GSK may be interested!) • Platforms, vaccines, devices, biomarkers, diagnostics, formulations, basic research • Diseases of the Developing World (direct link with Tres Cantos Open Lab) • Other modalities (e.g. nucleoside-based, Cell Therapeutics) • Completed discovery projects with assets for clinical development • Repurposing opportunities 4

Who we are Your gateway to GSK’s global A dedicated team of scientists, each of whom have a proven track expertise and resources record in early drug discovery Mike Bishop Jon Collins Dave Becherer Jakob Busch-Petersen Colin MacPhee Andy Pope DPAc Leader, NA DPAc Leader, NA DPAc Leader, NA DPAc Leader, NA DPAc Leader, NA DPAc Leader, NA Debra Peattie David Parry Katherine Widdowson Dennis Yamashita Entrepreneur in Entrepreneur in Entrepreneur in Entrepreneur in Residence, NA Residence, NA Residence, NA Residence, NA Duncan Holmes Mark Bamford Jeremy Griggs Stephane Huet John Liddle Danuta Mossakowska Iain Uings Ann Walker European Head DPAc Leader DPAc Leader DPAc Leader DPAc Leader DPAc Leader DPAc Leader DPAc Chemist DPAc Europe Europe Europe Europe Europe Europe Europe

What we look for Clear Therapeutic A coherent and supportable hypothesis that modulation of target will produce a hypothesis physiological effect which will be of therapeutic benefit to particular patients Specific drug target identified, and some understanding of type of pharmacology Target defined desired (Exclusive) Academic partner has know-how and/or expertise essential to progressing the target enabling expertise which is not (readily) found elsewhere Target knowledge suggests that a drug-like molecule can be generated Tractability Disease knowledge suggests that opportunity can be evaluated effectively in the clinic Requirement for GSK has capabilities and expertise which will help progress the project to the next GSK contribution milestone

Who it is best suited to Academic researchers who: • Want to be involved in turning their innovative research into medicines • Will contribute their own effort and resources to making projects work • Have recognised expertise in their chosen field • Bring something unique to the collaboration

What the benefits are • A single partner from idea to medicine • A key role in the project • Working alongside a drug discovery expert from GSK • Access to a broad array of people, tools and techniques within GSK • Joint publications and generation of new research tools • A financial share in the success of a future medicine

What are GSK’s capabilities? HTS capacity Medicinal chemistry Large scale protein Selectivity PK-PD 2 million and computational molecular production screening modelling compound set design Lead Target Assay Early Lead Late Lead Identification Feasibility Development Optimisation Optimisation Preclinical Flexible, Encoded Library Synthetic & Development Biopharm discovery Biopharm affinity high tech assay technology analytical platforms maturation (safety, chemistry, platforms >10 billion compounds chemistry pharmacy)

Shared activities between academia and GSK early stage Candidate Selection FTIH Start PhIII Start Launch Early Drug Early Drug Launch Pre-Clinical Phase I Phase II Phase III Discovery Discovery & royalties Late Lead Target Assay Lead Early Lead Optimisation Feasibility Development Identification Optimisation Drug Discovery Screen Lead Identified Lead Identified Initiated Initiated in vitro in vivo Typical GSK activities Chemistry DMPK Value of Screening Safety GSK internal Screening Chemistry Assay feasibility Assay development contribution Pharmacy Chemistry DMPK Tool generation € € €€ €€€ €€€ Typical academic activities Value of Physiological assays Physiological assays GSK support Reagent Physiological assays Assay development in vivo models in vitro and in vivo to academic generation € € €€ €€

Managing the relationship • Consistent agreement framework to promote rapid project initiation • Working together – Joint Research Committee • Joint investment of time/energy/resource to progress the project at both partner sites • Strong interactive relationships between project team • Equitable approach to IP – Academic will receive commercial rights if GSK terminates the collaboration

Decision making based on emerging data the decision to stop........for now..... • Exciting activity for drug-like molecules in recombinant in vitro and in vivo systems did not translate to patient-derived cell systems • Focusing together on key decision-making experiments allowed us to rapidly test our hypothesis • Further exploratory work required to understand the biology sufficiently to allow continuation of drug discovery • The project was returned to Dundee for further definition of underlying biology and maintaining Dundee’s opportunity to develop a medicine – Commercial rights reverted to Dundee – Key compounds were assigned to Dundee

Discovery Fast Track Challenge  An opportunity to collaborate together to test our compound collection using our pharmacological screening platforms to discover active compounds  We will share key results from the screen to provide you with the best possible chemical probes to interrogate your translational biological assays

How does Discovery Fast Track work?  The researcher provides a novel drug discovery concept that may include assay protocols, tools, reagents and models  GSK provides a team of scientists and its state-of-the-art capabilities to scale up and industrialize assays and data analysis  The target is screened against GSK compound collections and enabled to find novel quality pharmacologically active compounds  Discovery Fast Track is running in Europe in 2014 and we will let you know about the next Call for Proposals Reagents and High Throughput Encoded Library Hit Qualification Assays Screening Technologies Support www.gsk.com/discoveryfasttrack

In summary • We are looking for 10 -15 active DPAc collaborations worldwide - plus preDPAc collaborations • A team of dedicated scientists within GSK to lead the projects • Re-personalising the relationships between academia and GSK contact e-mail: dpac@gsk.com web site: www.dpac.gsk.com